The use of first-line biologics in patients with Crohn’s disease in Norway

BestPractice | Maalis 2019 | ECCO 2019 |

Karoline Anisdahl, Oslo University Hospital, Norway, and her colleagues aimed to assess whether there was a change over time in the proportion of patients receiving biologics between 2011 and 2016 and if the preferred first-line biologic changed after the introduction of biosimilar infliximab. Click and hear the highlights from the study.